STOCK TITAN

Kura Oncology Inc - KURA STOCK NEWS

Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.

Kura Oncology, Inc. (NASDAQ: KURA) is a clinical-stage biopharmaceutical company advancing precision therapies for genetically defined cancers. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's innovative pipeline, including its lead menin inhibitor ziftomenib for acute myeloid leukemia (AML).

Access authoritative updates on clinical trial progress, regulatory milestones, and strategic collaborations. Our curated collection features official press releases, financial disclosures, and scientific presentations - all organized for efficient tracking of Kura's developments in targeted cancer treatment.

Key content categories include clinical trial results, FDA communications, research partnerships, and quarterly financial reports. The repository serves as a reliable resource for understanding Kura's position in precision oncology and its approach to addressing high-need cancer populations.

Bookmark this page for direct access to Kura Oncology's verified announcements. For comprehensive analysis of these developments, consult your financial advisor and review SEC filings in conjunction with these updates.

Rhea-AI Summary

Kura Oncology announced its participation in the H.C. Wainwright BioConnect 2021 Conference, scheduled for January 13, 2021. President and CEO Troy Wilson will join a panel discussion on precision medicine, focusing on the role of biomarkers in drug discovery and commercialization. The panel, led by former FDA Commissioner Dr. Scott Gottlieb, will start at 9:00 a.m. PT. A live audio webcast will be accessible on Kura’s website, followed by an archived replay for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
conferences
-
Rhea-AI Summary

Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer medicines, will participate in the 39th Annual J.P. Morgan Healthcare Conference. CEO Troy Wilson is scheduled to present on January 12, 2021, at 1:30 p.m. PT / 4:30 p.m. ET. The virtual conference takes place from January 11-14, 2021. A live audio webcast of the presentation will be available on Kura's website and an archived replay will be accessible for 30 days post-event. Kura's leading drug candidates include tipifarnib and KO-539, targeting key cancer pathways.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.06%
Tags
conferences
-
Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) announced the successful closing of its public offering, selling 9,326,500 shares at $37.00 each, yielding approximately $345.1 million gross proceeds. The underwriters fully exercised their option to purchase an additional 1,216,500 shares. The offering was conducted under a shelf registration effective December 7, 2020. SVB Leerink, Credit Suisse, Barclays, and Stifel served as joint bookrunning managers. Kura aims to utilize these funds to advance its clinical-stage pipeline targeting cancer treatments, particularly focusing on precision medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
Rhea-AI Summary

Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer medicine, will participate in the JMP Securities Hematology Summit on December 15, 2020. CEO Troy Wilson will take part in a fireside chat at 11:00 a.m. ET. The summit is hosted virtually from December 15-16, 2020. A live audio webcast of the discussion will be available on Kura's website, with a replay accessible for 30 days. Kura's leading drug candidate is tipifarnib, aimed at treating HRAS mutant head and neck squamous cell carcinoma, alongside KO-539 for acute myeloid leukemia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.99%
Tags
conferences
-
Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) has announced the pricing of an underwritten public offering of 8,110,000 shares of its common stock at $37.00 per share, aiming for gross proceeds of approximately $300 million. The offering includes a 30-day option for underwriters to purchase an additional 1,216,500 shares. The expected closing date is December 11, 2020, pending customary conditions. The securities are offered under a previously filed shelf registration statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
-
Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) has initiated an underwritten public offering to sell $200 million in common stock, with an option for underwriters to purchase an additional $30 million. The offering is subject to market conditions, and no assurance is given regarding its completion. The shares will be offered under a shelf registration statement filed with the SEC. The transaction will be managed by SVB Leerink, Credit Suisse, Barclays, and Stifel.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.15%
Tags
Rhea-AI Summary

Kura Oncology announced preliminary data from its Phase 1/2A clinical trial of KO-539, an oral menin inhibitor, for treating relapsed/refractory acute myeloid leukemia (AML). Encouraging results showed evidence of biologic activity in all dose-escalation cohorts, with two complete remissions (CR) in patients with specific genetic mutations. The continuous dosing of KO-539 was well tolerated with manageable safety, and Kura plans to recommend a Phase 2 dose and advance to expansion cohorts in early 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Kura Oncology will host a virtual investor event on December 5, 2020, at 2:00 p.m. ET to discuss preliminary clinical data regarding its menin inhibitor, KO-539, following its presentation at the 62nd American Society of Hematology (ASH) Annual Meeting. The event will feature Kura's management team and investigators from the ongoing KOMET-001 trial. A live video webcast will be available on Kura's website, with an archived replay accessible after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
conferences
-
Rhea-AI Summary

Kura Oncology reported third quarter 2020 results, highlighting significant developments in its clinical pipeline and financial standing. Preliminary data from the KOMET-001 trial of KO-539, a menin inhibitor, showed promising safety and anti-leukemic activity. The drug is nearing a recommended Phase 2 dose with expansion cohorts planned for specific AML populations. Additionally, preclinical data supports the combination of tipifarnib with a PI3Kα inhibitor for treating HRAS-dependent HNSCC. Kura ended Q3 2020 with $325.4 million in cash, ensuring operational support into 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) announced participation in three upcoming virtual investor conferences. CEO Troy Wilson will present at the Credit Suisse 29th Annual Healthcare Conference on November 11, 2020, at 10:15 a.m. ET. CFO Marc Grasso will speak at the Stifel Virtual Healthcare Conference on November 16, 2020, at 1:20 p.m. ET. Additionally, a pre-recorded fireside chat with Dr. Wilson will be available on Kura's website during the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. Live audio webcasts will also be accessible on Kura's IR website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
conferences
Kura Oncology Inc

Nasdaq:KURA

KURA Rankings

KURA Stock Data

476.59M
78.01M
1.15%
102.19%
11.41%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO